Zanoni 2011.

Notes

Title: The predictive value of interim PET and immunohistochemical markers in Hodgkin lymphoma (HL). (Conference abstract) Aim To compare iPET with a series of histological and immunohistochemical parameters obtained on tissue‐micro‐arrays as possible predictive factors Study design Retrospective Country/treatment centre(s) Italy (Bologna) Number of included participants 209 Inclusion criteria Biopsy‐proven HL, complete clinical and iPET data Exclusion criteria None Treatment Not reported Primary outcome measure(s) Overall survival Progression‐free survival

ABVD: adriamycin/doxorubicin, bleomycin, vinblastine and dacarbazine; BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone; EBVD: epirubicin, bleomycin, vinblastine and dacarbazine; FDG: [18F]‐fluorodeoxy‐D‐glucose; HL: Hodgkin lymphoma; IF‐RT: involved‐field radiation therapy; iPET: interim positron emission tomography; MOPP: mustargen, Oncovin, procarbazine and prednisone; NPV: negative predictive value; PET: positron emission tomography; PET‐CT: positron emission tomography computed tomography; RT: radiotherapy.